Understand the source comparison
Peptide Clinical Trials Recruiting 2026 Participate: Trial Type Comparison
Phase I Healthy volunteers or target condition 8–20 visits over 6–12 weeks 6–12 weeks Safety: AEs, vitals, ECG, pharmacokinetics (serial blood draws) $4,000–$15,000 Intensive monitoring requires time flexibility; highest per-visit pay Phase II Confirmed diagno
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Phase I
- Healthy volunteers or target condition
- 8–20 visits over 6–12 weeks
- 6–12 weeks
- Safety: AEs, vitals, ECG, pharmacokinetics (serial blood draws)
- $4,000–$15,000
- Intensive monitoring requires time flexibility; highest per-visit pay
- Phase II
- Confirmed diagnosis of target condition (e.g., prediabetes, MCI)
- Weekly (titration) → monthly (maintenance), 12–20 visits
- 12–24 weeks
- Preliminary efficacy: biomarkers (HbA1c, cognitive scores), dose-finding
- $1,500–$4,000
- Shorter duration than Phase III; helps establish dosing for later trials
- Phase III
- Target condition; often stricter inclusion criteria than Phase II
- Weekly → biweekly → monthly, 15–30 visits
- 52–104 weeks
- Primary efficacy endpoint (e.g., ≥10% weight loss, MMSE improvement), safety in large cohorts
- $2,000–$6,000
- Longest commitment; double-blind (you don't know if receiving drug or placebo); results determine FDA approval
- Open-Label Extension
- Participants who completed Phase II/III
- Monthly visits
- 52–156 weeks (ongoing)
- Long-term safety, sustained efficacy
- Variable (often same per-visit rate as parent trial)
- Access to investigational peptide guaranteed (no placebo); continues until FDA approval or trial termination